September 18, 2006 -- Emiliem, Inc. a biotechnology company that discovers and develops molecularly targeted oncology drugs announced today that three preeminent scientists with extensive drug discovery and development experience have been named to its Scientific Advisory Board. The new appointments include Bahija Jallal, Ph.D., Vice President, Translational Sciences at MedImmune, Inc.; Manoj Desai, Ph.D., Vice President, Medicinal Chemistry at Gilead Sciences; and Sean Ekins, Ph.D., D.Sc., Sr. Vice President, Computational Biology at Arnold Consultancy and Technology LLC. Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem stated, “We are very pleased that these three individuals are joining our SAB at this stage of our company’s life cycle. All three are top scientists in their respective fields, and additionally they all have significant experience in the practical aspects of designing drugs to modulate specific therapeutic targets”.
